Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7ad58d3c0b071069a8ee0cb8c8ba2e8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4839 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-6823 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-686 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H40-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4875 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-0537 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 |
filingDate |
2019-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adc556ecc5ddf1c6590fff27a08effe0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa612ae3f63570baa1641950529c0ccc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eef525c59196fe0ad89a1db9e3b49104 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81d0b0bffd4cb911a4de28e74700cd12 |
publicationDate |
2019-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2019141575-A1 |
titleOfInvention |
Assistance in the treatment of cardiac insufficiency |
abstract |
The present invention relates to the treatment of cardiac insufficiency. A sensor for measuring the tissue fluid content in the region of the rib cage is implanted in a person suffering from cardiac insufficiency. If the tissue fluid content does not get back to normal within a defined period of time and under treatment with the available standard therapy, treatment with a V1a/V2 vasopressin receptor antagonist is recommended. Dosage of the V1a/V2 vasopressin receptor antagonist and duration of the treatment with the V1a/V2 vasopressin receptor antagonist can be determined on the basis of the acquired sensor data. |
priorityDate |
2018-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |